



Cannabis

Drawing upon the expertise of lawyers across a number of practice areas, Stikeman Elliott delivers innovative legal solutions to cannabis sector clients on a full range of relevant matters. From providing strategic advice on complex acquisitions and regulatory matters to guiding companies doing IPOs and subsequent offerings, Stikeman Elliott is able to leverage its unmatched experience in Canadian business law to assist our clients achieve their objectives in this rapidly expanding sector.

As one of Canada's most active legal advisors in the sector, we have been at the forefront of the recent wave of cannabis industry transactions. In addition to advising on public and private mergers and acquisitions and other strategic transactions, we have worked on a large number of successful listings on the TSX Venture Exchange, the Toronto Stock Exchange, the Canadian Securities Exchange and the Aequitas NEO Exchange for Canada's first cannabis-focused SPAC.

Our multidisciplinary team has a deep bench of experience in the life science & healthcare industry and includes lawyers from our Intellectual Property and Employment & Labour practice groups, among others. The team advises on supply agreements, joint venture arrangements, licensing agreements, regulatory matters, intellectual property matters, and other strategic initiatives. Clients include cannabis producers, investors, financiers, advisory firms, underwriters, agents, and pharmaceutical companies in Canada and around the world. This wealth of experience has given us an unparalleled understanding of the industry and enables us to work with clients to manage and minimize risk while achieving their business goals.

Our Expertise

- Clinical trials
- Copyright and trademark matters
- Cross-licensing
- DINs
- E-commerce
- *Food and Drugs Act* compliance
- GMP
- Health Canada approvals and challenges
- Initial public offerings (IPOs) and go-public transactions
- Investigations
- Joint ventures and strategic alliances
- Labelling and marketing
- Licensing, manufacturing, wholesale, supply, and distribution agreements
- Marijuana in the workplace
- Material transfer agreements
- Medical marijuana
- Patent portfolio development
- Product authorizations, licensing and inspections
- Product listing agreements
- Provincial formularies
- R&D agreements and grants
- Recalls

Recent Work

- MedReleaf Corp. in its C\$3.2B acquisition by Aurora Cannabis Inc.

- CanniMed Therapeutics Inc., as special committee counsel, in connection with CanniMed's hostile take-over bid defense and subsequent negotiation of a supported take-over bid by Aurora Cannabis Inc. with an implied total equity value of over C\$1.2B.
- The agents, led by Beacon Securities Limited, in connection with the C\$50M private placement offering by Cannex Capital Group Inc. of subscription receipts to fund its acquisition of BrightLeaf Development LLC and concurrent reverse take-over of Arco Resources Corp.
- AltaCorp Capital Inc., the sole agent in a C\$20M private placement offering of common shares of Prairie Plant Systems Inc., the parent company of CanniMed Ltd., the first company licensed to produce medical marijuana in Canada.
- Syndicate of underwriters, led by AltaCorp Capital Inc., as counsel, in connection with the C\$60M initial public offering of common shares of CanniMed Therapeutics Inc.
- National Concessions Group Inc. (a.k.a. Organa Brands) in its collaborative joint venture with Green House Holdings North America Inc., GHSC Trading B.V., and Canopy Growth Corporation. Operating under the name Agripharm Corp, the joint venture will create a new Canadian home-base for Green House and Organa Brands where they will work together with Canopy Growth to produce cannabis products for the Canadian market.
- Tetra Bio-Pharma Inc., a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development, in connection with the sale of its subsidiary GrowPros MMP Inc. to North Bud Farms Inc.
- Cannabis Strategies Acquisition Corp. and Mercer Park CB, L.P. in the C\$134.7M initial public offering of Class A restricted voting units of Cannabis Strategies Acquisition Corp., Canada's first cannabis-focused special purpose acquisition corporation.
- The Supreme Cannabis Company, Inc. (formerly known as Supreme Pharmaceuticals Inc.) in its C\$10M strategic equity investment in Medigrow Lesotho (PTY) Limited and establishment of a global distribution partnership.
- Certain shareholders of Bedrocan Canada, as counsel, in the Canopy Growth / Bedrocan merger, one of the first public M&A transactions in the Canadian cannabis industry.
- CannaKorp Inc., makers of the world's first single-use, pod-based cannabis vaporizing system, the CannaCloud™, in its multi-year licensing and distribution agreement with MedReleaf Corp., North America's first and only ISO 9001 and ICH-GMP certified producer of cannabis-based pharmaceutical products.
- The Supreme Cannabis Company, Inc. (formerly known as Supreme Pharmaceuticals Inc.), a Canadian-based producer of high-quality cannabis products, in its bought deal private placement of convertible debenture units consisting of convertible debentures and warrants for aggregate gross proceeds of C\$40.25M.